Julie Villeneuve
About Julie Villeneuve
Julie Villeneuve is the Director of HTA and Market Access at Bristol-Myers Squibb, with extensive experience in pharmaceutical sciences and market access strategies.
Title
Julie Villeneuve currently holds the position of Director HTA and Market Access at Bristol-Myers Squibb. She has been leading this department since January 2018, utilizing her extensive background in pharmaceutical sciences, hospital pharmacy, and market access strategies.
Current Role at Bristol-Myers Squibb
Julie Villeneuve is based in the Greater Montreal Metropolitan Area but works in New Jersey, United States, for Bristol-Myers Squibb. As Director of HTA and Market Access, she leads the team responsible for health technology assessments and market access strategies. Her role involves navigating complex healthcare landscapes in both Canada and the United States.
Education and Expertise
Julie Villeneuve has a strong educational background in pharmaceutical sciences. She earned a PhD in Pharmaceutical Sciences from Université de Montréal, completed in 2009, and a MSc in Hospital Pharmacy from the same institution in 2003. She also holds a BPharm in Pharmacy from Université Laval, completed in 2002. Additionally, she achieved the HEC-CEDEP certificate in Mastering Business Excellence from HEC Montréal in 2018 after 11 months of study.
Academic Background
Julie Villeneuve's academic journey began with a BPharm in Pharmacy from Université Laval, which she completed in 2002. She then pursued an MSc in Hospital Pharmacy at Université de Montréal, completed in 2003. Her education culminated with a PhD in Pharmaceutical Sciences from Université de Montréal, achieved in 2009. These qualifications have provided her with a solid foundation in both the theoretical and practical aspects of pharmaceutical sciences.
Healthcare Landscape Knowledge
Julie Villeneuve has a comprehensive understanding of the healthcare landscape in both Canada and the United States. This extensive knowledge contributes to her effectiveness in her role at Bristol-Myers Squibb, where she navigates the complexities of health technology assessments and market access strategies across different healthcare systems.